文献速递垂体与肾上腺疾病

靶向CXCR4的68Ga-Pentixafor PET/CT在原发性醛固酮增多症分型中的价值

The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该研究前瞻性纳入120例原发性醛固酮增多症(PA)或无功能腺瘤(NFA)患者,评估68Ga-Pentixafor PET/CT对PA分型的价值。结果显示,对醛固酮 producing 腺瘤(APA)的视觉分析灵敏度92.40%、特异度94.40%、准确率93.33%,与CYP11B2免疫组化一致率81.69%,提示该技术可高准确度分型PA并指导临床治疗决策。

要点

  • 68Ga-Pentixafor PET/CT视觉分析诊断APA的灵敏度92.40%、特异度94.40%、准确率93.33%。
  • 结节直径大于1 cm且最大标准摄取值≥7.3时,诊断APA特异度100%。
  • PET/CT与CYP11B2免疫组化一致率81.69%,与AVS分型一致率60%(5例中)。

核心结论

  • 68Ga-Pentixafor PET/CT是一种可靠的无创功能成像技术,对PA分型具有高准确度,并为临床治疗决策提供有价值的指导。

研究设计与样本

  • 前瞻性纳入120例PA或NFA患者,所有患者接受68Ga-Pentixafor PET/CT,其中11例行肾上腺静脉采血(AVS),77例行肾上腺切除术,76例获病理诊断,71例行醛固酮合酶(CYP11B2)免疫组化,62例行CXCR4免疫组化,所有患者均随访。

主要发现

  • 120例中,66例诊断为醛固酮 producing 腺瘤(APA),33例为特发性醛固酮增多症(IHA),21例为NFA。
  • 对APA患者,68Ga-Pentixafor PET/CT视觉分析的灵敏度为92.40%、特异度为94.40%、准确率为93.33%。
  • 结节直径大于1 cm的APA患者中,最大标准摄取值≥7.3时特异度为100%;结节直径小于1 cm的APA患者中,68Ga-Pentixafor PET/CT也表现出高灵敏度。
  • AVS在5例患者中成功完成,AVS与68Ga-Pentixafor PET/CT对PA分型的一致率为60%。
  • 77例行肾上腺切除术的患者中,61例PET/CT显示阳性病灶,均从手术中获益;68Ga-Pentixafor PET/CT成像与CYP11B2的一致率为81.69%。

临床怎么用

  • 原文结论认为68Ga-Pentixafor PET/CT对PA分型具有高准确度,并为临床治疗决策提供有价值的指导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Primary aldosteronism (PA) is one of the leading causes of secondary hypertension, and its diagnostic subtyping consistently presents a clinical challenge. OBJECTIVE: This study aimed to investigate the potential of 68Ga-Pentixafor positron emission tomography/computed tomography (PET/CT) in PA classification and its applicability in guiding the development of clinical treatment plans by increasing the sample size. METHODS: We prospectively enrolled 120 patients with either PA or nonfunctional adenoma (NFA) for analysis. All patients underwent 68Ga-Pentixafor PET/CT. Of these, 11 patients underwent adrenal venous sampling (AVS), 77 underwent adrenalectomy, 76 received pathological diagnoses, and 71 underwent immunohistochemical detection of aldosterone synthase (CYP11B2). Immunohistochemistry for C-X-C chemokine receptor 4 (CXCR4) was performed in 62 cases. Follow-up was conducted for all patients. RESULTS: Among the 120 patients, 66 were diagnosed with aldosterone-producing adenoma (APA), 33 with idiopathic hyperaldosteronism (IHA), and 21 with NFA. For APA patients, the sensitivity, specificity, and accuracy of visual analysis using 68Ga-Pentixafor PET/CT were 92.40%, 94.40%, and 93.33%, respectively. Furthermore, for APA patients with a nodule greater than 1 cm in diameter, when the maximum standard uptake value was 7.3 or greater, the specificity was 100%; and for APA patients with a nodule less than 1 cm in diameter, 68Ga-Pentixafor PET/CT also exhibited high sensitivity. AVS was successfully performed in 5 patients. Among the 5 patients, the concordance rate between the AVS and 68Ga-Pentixafor PET/CT for PA subtyping was 60%. In the 77 patients who underwent adrenalectomy, 61 PET/CT scans displayed positive lesions, all of which benefited from the surgery. Additionally, the concordance rate between 68Ga-Pentixafor PET/CT imaging and CYP11B2 was 81.69%. CONCLUSION: 68Ga-Pentixafor PET/CT is a reliable and noninvasive functional imaging technique that demonstrates high accuracy in classifying PA and provides valuable guidance for clinical treatment decision-making.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zheng Y, Long T, Peng N, et al. The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism. J Clin Endocrinol Metab. 2023. PMID: 37477496. doi:10.1210/clinem/dgad421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。